May 14, 2025, 08:49

Cancer Grand Challenge: Rewiring Cancer Cells

This challenge aims to pioneer novel approaches that rewire the internal signalling systems of cancer cells to reduce malignancy or induce self-destruction. By harnessing advances in synthetic biology and systems biology, teams will explore ways to shift cancer cell behavior away from oncogenesis, creating new therapeutic strategies that avoid common resistance mechanisms seen with targeted inhibitors.

Eligibility Criteria:

Open to global, interdisciplinary research teams
Must combine expertise in areas such as synthetic biology, AI, medicinal chemistry, structure-based drug design, cancer biology, immunology, and cellular signalling
Proposals must not focus on targeted protein degradation

Funding Details:

Up to £20 million (USD 25 million) per team
Duration: Not specified

Deadline:

Expressions of Interest due: 18 June 2025

More Information:

Submit your Expression of Interest

cancer Cancer Cell Signalling Cancer Grand Challenge cancer therapy cancer treatment innovation cell phenotype modulation immunogenic cell death OncoDaily oncogenic signalling Oncology rewiring cancer Synthetic Biology tumour heterogeneity

25 Posts Not To Miss From ESMO GI 2025

Botensilimab and Balstilimab Show Durable Survival in MSS Colorectal Cancer: ESMO GI 2025 Update

Julian McMahon Dies at 56: A Look Back at His Private Cancer Battle and Legendary Acting Career

Vivek Subbiah: It’s Time We Evolve WHO Cancer Classification

ESMO 50th Anniversary: Half a Century of Evidence-Based Cancer Care